Breaking News

Merck Serono Invests in Shanghai Manufacturing Facility

To begin commercial production in 2017

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck Serono is investing €80 million in a new pharmaceutical manufacturing facility located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region. The new facility will focus on the bulk production and packaging of Glucophage, Concor and Euthyrox, Merck’s leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively. The new facility will cover an area of 40,000 square meters, with the option to expand b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters